Myriad Asset Management Advisors LLC Takes Position in Novo Nordisk A/S $NVO

Myriad Asset Management Advisors LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 38,512 shares of the company’s stock, valued at approximately $1,846,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Capital Investment Counsel LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $3,727,000. Marathon Capital Management boosted its stake in Novo Nordisk A/S by 43.9% in the 4th quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock worth $4,208,000 after purchasing an additional 25,230 shares in the last quarter. Burkett Asset Management Ltd bought a new position in Novo Nordisk A/S in the 4th quarter worth about $1,823,000. Tevis Investment Management grew its position in Novo Nordisk A/S by 65.7% during the 1st quarter. Tevis Investment Management now owns 74,090 shares of the company’s stock valued at $2,813,000 after purchasing an additional 29,390 shares during the last quarter. Finally, XXEC Inc. grew its position in Novo Nordisk A/S by 487.1% during the 1st quarter. XXEC Inc. now owns 545,020 shares of the company’s stock valued at $20,029,000 after purchasing an additional 452,185 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on NVO. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Berenberg Bank set a $47.00 price objective on Novo Nordisk A/S in a research report on Wednesday. Finally, BMO Capital Markets reiterated a “market perform” rating and set a $47.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Four equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $46.52 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The firm has a market cap of $207.71 billion, a price-to-earnings ratio of 11.37, a price-to-earnings-growth ratio of 4.30 and a beta of 0.76. The business has a 50-day simple moving average of $47.24 and a two-hundred day simple moving average of $44.61. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The firm had revenue of $11.98 billion for the quarter. On average, analysts expect that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be issued a $0.5786 dividend. The ex-dividend date is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 42.79%.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk CEO Mike Doustdar said demand for weight-loss medicines still has a “long runway,” arguing that GLP-1 adoption remains in its early stages and could ultimately reduce healthcare costs and improve productivity. Novo Nordisk CEO sees long runway for weight-loss drugs
• Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, expanding the company’s diabetes portfolio and providing a potential new commercial growth driver beyond obesity treatments. Awiqli now available in the US
• Positive Sentiment: Erste Group raised its 2026 earnings-per-share estimate for Novo Nordisk to $3.27 from $3.20, while bullish commentary argues that the company’s broader cardiometabolic pipeline is being undervalued. Analysts raise Novo Nordisk earnings estimates
• Neutral Sentiment: Novo Nordisk is suing Eli Lilly over weight-loss-drug advertising. Management says the lawsuit is intended to ensure fair competition, but the dispute also highlights the intensifying rivalry between the two leading obesity-drug companies. Novo Nordisk CEO defends lawsuit against Eli Lilly
• Negative Sentiment: Analysts cited flat Wegovy sales, pricing challenges, pipeline setbacks and the risk that Eli Lilly is pulling ahead in the oral obesity market. These concerns, combined with the Berenberg downgrade, are weighing on sentiment toward NVO. Berenberg cuts Novo Nordisk as Lilly takes the oral market

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.